Leading Pharmaceutical Stocks in the Small-Cap Sector by 2025
Top Small-Cap Pharma Stocks on NASDAQ: A Look at the Leaders
In the dynamic world of biotech, several small-cap pharma stocks have been making waves on NASDAQ. As of early August 2025, ABVC BioPharma, I-Mab, Galectin Therapeutics, CytomX Therapeutics, and Gossamer Bio stand out as the most notable for their developments and financial performance.
ABVC BioPharma leads the pack with a year-to-date gain of approximately 406%. This remarkable growth can be attributed to the advancement of six drugs and a medical device, as well as a 234% increase in total revenues for 2024, amounting to $509,589. The company's financial health has also improved, with total assets doubling to $16.2 million by Q2 2025, a 103% rise from the prior year. In July 2025, ABVC collected $350,000 in licensing revenue, a sign of their efforts to monetize their pipeline sustainably.
I-Mab, Galectin Therapeutics, CytomX Therapeutics, and Gossamer Bio are also identified as top small-cap pharma stocks to watch in 2025. However, detailed financials or recent development specifics were not provided in the search results. Their inclusion signals promising pipelines or strategic positioning, common traits in small-cap biotech firms.
Galectin Therapeutics is a clinical-stage biopharma company developing therapies for chronic liver disease and cancer. Their lead drug candidate, carbohydrate-based belapectin, targets multiple inflammatory, fibrotic, and malignant diseases. Belapectin has been granted fast-track designation by the FDA, indicating its potential to address unmet medical needs.
Gossamer Bio is another clinical-stage biopharma company, this time focused on the development and commercialization of therapies to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Their lead drug candidate, seralutinib, is currently being evaluated in a Phase 3 clinical trial for the treatment of pulmonary arterial hypertension. Gossamer Bio expects to activate the first clinical sites for a global registrational Phase 3 study on pulmonary hypertension associated with interstitial lung disease patients in Q4 2025.
CytomX Therapeutics is a clinical-stage biopharma firm with a focus on developing safer, more effective oncology treatments. Their share price started at US$1.06 in 2025, but shot up to US$2.50 on May 13 after a series of announcements. These included the closing of a US$100 million underwritten offering of common stock and the initiation of a Phase 1 dose escalation study with CX-801 in combination with Merck & Company's KEYTRUDA (pembrolizumab) in patients with metastatic melanoma.
In summary, while ABVC BioPharma currently stands out for its significant stock appreciation, pipeline developments, and improving financial position, the other top small-caps—I-Mab, Galectin Therapeutics, CytomX Therapeutics, and Gossamer Bio—remain key companies to monitor for future developments and financial disclosures. Their inclusion in the top five small-cap NASDAQ pharma stocks underscores their potential for growth and impact in the biotech industry.
In the realm of tech investing, ABVC BioPharma's strong performance in the stock market, driven by advancements in technology-based drug development and a robust financial standing, makes it a notable choice for tech-savvy investors. Meanwhile, technology plays a crucial role in the pipelines of WTech Stocks such as I-Mab, Galectin Therapeutics, CytomX Therapeutics, and Gossamer Bio, signaling their potential for future growth and innovation in the biotech industry.
